Revenue grew from $43.2M to $83.9M and gross margin reached 76.2%, yet trailing operating margin of -20.6% and net margin of -21.5% suggest profitability claims warrant reconciliation before being relied upon.
Adaptive Biotechnologies Corporation (ADPT) annual income statement — 9-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Sales/Revenue | 298.01M | 276.98M | 178.96M | 170.28M | 185.31M | 154.34M | 98.38M | 85.07M | 55.66M | 38.45M |
| Revenue Growth % | 17.91% | 54.77% | 5.1% | -8.11% | 20.06% | 56.88% | 15.65% | 52.83% | 44.77% | - |
| Cost of Goods Sold | 77.45M | 71.36M | 72.08M | 75.55M | 57.91M | 49.3M | 22.53M | 22.27M | 19.67M | 15.68M |
| COGS % of Revenue | - | 25.76% | 40.28% | 44.37% | 31.25% | 31.94% | 22.9% | 26.18% | 35.33% | 40.78% |
| Gross Profit | 220.56M | 205.62M | 106.88M | 94.72M | 127.4M | 105.04M | 75.85M | 62.8M | 35.99M | 22.77M |
| Gross Margin % | 74.01% | 74.24% | 59.72% | 55.63% | 68.75% | 68.06% | 77.1% | 73.82% | 64.67% | 59.22% |
| Gross Profit Growth % | - | 92.39% | 12.83% | -25.65% | 21.28% | 38.48% | 20.79% | 74.46% | 58.09% | - |
| Operating Expenses | 268.76M | 262.74M | 269.43M | 321.76M | 327.58M | 314.01M | 228.67M | 141.19M | 85.75M | 66.4M |
| OpEx % of Revenue | - | 94.86% | 150.55% | 188.96% | 176.78% | 203.45% | 232.43% | 165.96% | 154.05% | 172.71% |
| Selling, General & Admin | 184.31M | 167.27M | 157.56M | 172.51M | 184.13M | 169.97M | 110.89M | 68.78M | 44.9M | 32.71M |
| SG&A % of Revenue | - | 60.39% | 88.05% | 101.31% | 99.36% | 110.12% | 112.72% | 80.86% | 80.66% | 85.09% |
| Research & Development | 83.18M | 93.77M | 102.95M | 122.12M | 141.76M | 142.34M | 116.07M | 70.7M | 39.16M | 32M |
| R&D % of Revenue | - | 33.85% | 57.53% | 71.72% | 76.5% | 92.22% | 117.98% | 83.11% | 70.35% | 83.22% |
| Other Operating Expenses | 1.28M | 1.7M | 8.91M | 27.13M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.69M |
| Operating Income | -48.21M | -57.12M | -162.55M | -227.03M | -200.19M | -208.97M | -152.82M | -78.39M | -49.76M | -44.48M |
| Operating Margin % | -16.18% | -20.62% | -90.83% | -133.33% | -108.03% | -135.39% | -155.33% | -92.15% | -89.39% | -115.68% |
| Operating Income Growth % | - | 64.86% | 28.4% | -13.41% | 4.2% | -36.74% | -94.94% | -57.55% | -11.87% | - |
| EBITDA | -32.87M | -39.29M | -143.29M | -204.8M | -179.27M | -195.01M | -144.34M | -70.6M | -43.76M | -38.68M |
| EBITDA Margin % | -11.03% | -14.19% | -80.07% | -120.28% | -96.74% | -126.35% | -146.72% | -82.99% | -78.61% | -100.6% |
| EBITDA Growth % | 45.3% | 72.58% | 30.03% | -14.25% | 8.07% | -35.1% | -104.45% | -61.35% | -13.13% | - |
| D&A (Non-Cash Add-back) | 15.33M | 17.83M | 19.26M | 22.23M | 20.92M | 13.95M | 8.47M | 7.79M | 6M | 5.8M |
| EBIT | -45.07M | -47.68M | -148.01M | -211.5M | -196.13M | -207.3M | -152.82M | -78.39M | -49.76M | -43.63M |
| Net Interest Income | 1.21M | -2.33M | 2.95M | 1.73M | -182K | 1.67M | 6.59M | 9.79M | 3.31M | 1.64M |
| Interest Income | 10.25M | 9.44M | 14.53M | 15.53M | 4.06M | 1.67M | 6.59M | 9.79M | 3.31M | 1.64M |
| Interest Expense | 9.04M | 11.78M | 11.58M | 13.8M | 4.24M | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -22.54M | -2.33M | 2.95M | 1.73M | -182K | 1.67M | 6.59M | 9.79M | 3.31M | 1.64M |
| Pretax Income | -70.75M | -59.46M | -159.59M | -225.3M | -200.37M | -207.3M | -146.23M | -68.61M | -46.45M | -42.83M |
| Pretax Margin % | -23.74% | -21.47% | -89.18% | -132.32% | -108.13% | -134.31% | -148.63% | -80.65% | -83.44% | -111.4% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -70.52M | -59.5M | -159.49M | -225.25M | -200.19M | -207.28M | -146.23M | -68.61M | -46.45M | -42.83M |
| Net Margin % | -23.66% | -21.48% | -89.12% | -132.29% | -108.03% | -134.3% | -148.63% | -80.65% | -83.44% | -111.4% |
| Net Income Growth % | 11.42% | 62.69% | 29.19% | -12.52% | 3.42% | -41.75% | -113.14% | -47.71% | -8.44% | - |
| Net Income (Continuing) | -70.75M | -59.46M | -159.59M | -225.3M | -200.37M | -207.3M | -146.23M | -68.61M | -46.45M | -42.83M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 7.68M | 6.21M | -224K | -121K | -67K | 110K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.38 | -0.39 | -1.08 | -1.56 | -1.40 | -1.46 | -1.06 | -0.47 | -0.44 | -0.41 |
| EPS Growth % | 16.51% | 63.89% | 30.77% | -11.43% | 4.11% | -37.74% | -125.53% | -6.82% | -7.32% | - |
| EPS (Basic) | - | -0.39 | -1.08 | -1.56 | -1.40 | -1.46 | -1.06 | -0.47 | -0.44 | -0.41 |
| Diluted Shares Outstanding | 186.88M | 151.72M | 147.1M | 144.38M | 142.52M | 140.35M | 131.22M | 124.34M | 105.43M | 105.43M |
| Basic Shares Outstanding | 160.4M | 151.72M | 147.1M | 144.38M | 142.52M | 140.35M | 131.22M | 124.34M | 105.43M | 105.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ADPT stock.
For fiscal year 2025, Adaptive Biotechnologies Corporation (ADPT) reported total revenue of $277.0M. This represents a 620.4% increase compared to $38.4M in 2017.
Adaptive Biotechnologies Corporation (ADPT) reported a net loss of $59.5M for the fiscal year ending 2025.
Adaptive Biotechnologies Corporation (ADPT) reported an operating income of $-57.1M, resulting in an operating profit margin of -20.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Adaptive Biotechnologies Corporation (ADPT) generated $205.6M in gross profit for the year, representing a gross profit margin of 74.2%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses and leverage
Metrics are mathematically derived from official filings.
Revenue Re-Accelerating Off a Low Base
Based on reported quarterly figures, ADPT's revenue rose from $43.2M in 2024Q2 to $83.9M in 2026Q3, with the latest quarter showing year-over-year growth of roughly 55 percent that suggests the top line is inflecting meaningfully upward.
The growth pattern appears to be driven at least partly by lumpy collaboration and milestone revenue, which may explain the sharp swing between the 2025Q3 peak of $94.0M and the subsequent sequential decline to $71.6M. Investors should separate recurring clonoSEQ volume growth from one-time partnership payments before extrapolating the current rate. The durability of expansion remains unproven until several quarters show sequential growth without a large non-recurring contribution.
Gross Margin Holds While Operating Margin Turns Near Breakeven
As reported in the quarterly income statements, gross margin climbed from 55.3% in 2024Q2 to 76.2% in 2026Q3, while operating margin improved from -109.6% to -0.5%, indicating substantial structural progress.
The gross margin expansion suggests that the fixed laboratory cost base is being absorbed by higher test volumes, consistent with a high-value diagnostic model. The latest quarter's near-zero operating margin is encouraging, though it coincides with a revenue spike that may not repeat. Sustainability depends on whether gross margins remain above 70 percent through quarters with lower milestone contribution.
Operating Leverage Emerging but Unconfirmed
According to the reported figures, operating expenses of roughly $64M in 2026Q3 against $64.0M of gross profit left operating income near breakeven, versus an operating loss of $33.8M in 2024Q4 when gross profit was far smaller.
Operating income appears to be scaling faster than the operating cost base over the last six quarters, which is the core signature of positive operating leverage. However, R&D and SG&A have stayed in the $40M to $48M combined range even as revenue doubled, suggesting discipline but also that the cost base has not been fully reset. Whether this leverage persists depends on whether the latest quarter reflects a durable run rate.
Net Income Swing Warrants Verification
Reported net income moved from a $-46.2M loss in 2024Q2 to $2.9M in 2026Q3, but the latest quarter's net margin of 3.4% sits well above its operating margin of -0.5%, which warrants investigation of non-operating items.
The gap between operating income and net income in 2026Q3 suggests non-operating gains, such as interest income or other items, may have contributed to the reported profit. Stock-based compensation of $10.4M in the latest quarter is a meaningful non-cash charge that flatters cash economics relative to GAAP net income in some periods. Investors should review the filing to confirm the composition of the positive bottom-line result before treating it as operating profitability.
Cost Base Stable While Revenue Scales
Based on reported figures, cost of revenue fell as a share of sales from roughly 45 percent in 2024Q2 to 23.8 percent in 2026Q3, with R&D and SG&A held in a relatively narrow band throughout the period.
The stable absolute spending on R&D and SG&A, despite doubling revenue, suggests management has prioritized expense discipline over aggressive reinvestment. This restraint supports margin improvement but may also constrain the pace of therapeutic pipeline development. Investors should monitor whether R&D spending is sustained at current levels, since underinvestment in the immune medicine platform could weaken the long-term moat.
Profitability Claim Not Yet Reconciled
Trailing margins of -20.6% operating and -21.5% net remain deeply negative, which conflicts with management's framing of total company profitability and suggests the bull case may rest on adjusted or single-quarter measures.
A single profitable quarter driven by revenue lumpiness does not establish a sustainable earnings base, and the 2025Q3 peak was followed by a sharp reversal. Elevated leverage with a debt-to-equity ratio of 1.25 and an ROE of -27.8% leaves limited margin for error if revenue slips again. Investors should treat the profitability inflection as a hypothesis to be confirmed through consecutive GAAP-profitable quarters.